Related Experiment Video
Updated: Jun 4, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Anti-inflammatory treatment
Current Problems in Dermatology
|February 18, 2011
Summary
Topical calcineurin inhibitors like tacrolimus and pimecrolimus offer effective treatment for inflammatory mucosal disorders, including oral lichen planus and anogenital lichen sclerosus.
Area of Science:
- Dermatology and immunology, focusing on mucosal inflammatory conditions.
Background:
- Conventional treatment for inflammatory mucosal disorders relies on potent topical corticosteroids.
- Topical cyclosporine has a long history in managing oral mucous membrane affections.
- Tacrolimus and pimecrolimus represent newer topical calcineurin inhibitors for mucosal diseases.
Purpose of the Study:
- To review the efficacy and safety of topical calcineurin inhibitors.
- To assess their use in various oral and genital inflammatory conditions.
- To highlight their role in protracted conditions requiring long-term management.
Main Methods:
- Review of current evidence on topical calcineurin inhibitors.
- Focus on conditions including anogenital lichen sclerosus, oral and genital lichen planus, plasma cell balanitis/vulvitis, mucous membrane pemphigoid, and pemphigus vulgaris.
Main Results:
- Evidence supports the effectiveness of pimecrolimus and tacrolimus in topical treatment.
- These agents are effective for inflammatory oral mucosal diseases.
- They are also effective for genital dermatoses, particularly oral lichen planus and genital lichen sclerosus.
Conclusions:
- Topical calcineurin inhibitors are valuable additions to the treatment of inflammatory mucosal diseases.
- Tacrolimus and pimecrolimus demonstrate efficacy in managing specific oral and genital conditions.
- Their use is supported by current evidence for long-term treatment of chronic conditions.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...